argenx_logo_default.png
argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021
July 22, 2021 01:00 ET | argenx SE
July 22, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and...
argenx_logo_default.png
argenx to Host Virtual R&D Day on July 20, 2021
July 14, 2021 01:00 ET | argenx SE
July 14, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and...
argenx_logo_default.png
argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
June 16, 2021 18:30 ET | argenx SE
Results from ADAPT showed treatment with efgartigimod provided clinically meaningful improvements in strength and quality of life measures in generalized myasthenia gravis (gMG) Efgartigimod is...
argenx_logo_default.png
argenx to regain global rights to cusatuzumab
June 07, 2021 01:00 ET | argenx SE
Regulated Information/Inside Information June 7, 2021 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...
argenx_logo_default.png
argenx Appoints Karl Gubitz as Chief Financial Officer
June 01, 2021 04:01 ET | argenx SE
June 1, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and...
argenx_logo_default.png
argenx to Present at Upcoming Investor Conferences
June 01, 2021 01:00 ET | argenx SE
June 1, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and...
argenx_logo_default.png
argenx Reports First Quarter 2021 Financial Results and Provides Business Update
May 14, 2021 01:00 ET | argenx SE
Japanese Marketing Authorization Application (J-MAA) for efgartigimod accepted for review by Japan’s Pharmaceuticals and Medical Device Agency (PMDA) for generalized myasthenia gravis (gMG) ...
argenx_logo_default.png
argenx announces results of Annual General Meeting of Shareholders
May 11, 2021 05:00 ET | argenx SE
May 11, 2021Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and...
argenx_logo_default.png
argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021
May 07, 2021 01:00 ET | argenx SE
May 7, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer,...
argenx_logo_default.png
argenx Management to Present at Upcoming Virtual Investor Conferences
April 28, 2021 01:00 ET | argenx SE
April 28, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and...